XM अमेरिका के निवासियों को अपनी सेवाएँ मुहैया नहीं करता है।
T
T

Teva


समाचार

Teva Pharm CEO says will work productively with Trump administration

Teva Pharm CEO says will work productively with Trump administration JERUSALEM, Nov 6 (Reuters) - Teva Pharmaceutical Industries TEVA.TA expects to work productively with the incoming Trump administration in the United States, chief executive Richard Francis said on Wednesday. "Our job, as always, is to work productively with any administration, and we've shown we can do that, and we will absolutely do that," Francis told Reuters after the Israeli drugmaker issued strong third-quarter results.
T

Teva Pharma's listed shares up after lifting 2024 forecast, upbeat Q3 results

BUZZ-Teva Pharma's US-listed shares up after lifting 2024 forecast, upbeat Q3 results ** U.S.-listed shares TEVA.N of Israel-based Teva Pharmaceutical rise 2.1% to $19.16 premarket ** Co raises its 2024 rev. and earnings forecast after beating Q3 profit forecasts, boosted by strong sales of copycat medicines and its branded drugs to treat migraines and Huntington's disease ** Raises 2024 rev.
T

Teva Pharmaceutical raises 2024 outlook as Q3 profit beats estimates

UPDATE 2-Teva Pharmaceutical sees more growth in 2025 after strong Q3 Adds CEO comments, financial details, company background, paragraphs 2-3, 7-9 and 14 Teva raises 2024 revenue and earnings guidance after strong Q3 results CEO Richard Francis expects continued growth in 2025, including biosimilar business Teva fined over $500 million by European Commission, plans to appeal By Steven Scheer JERUSALEM, Nov 6 (Reuters) - Teva Pharmaceutical Industries TEVA.TA raised its 2024 revenue and earnings
T

Teva Pharmaceutical third-quarter profit, revenue top estimates

Teva Pharmaceutical third-quarter profit, revenue top estimates JERUSALEM, Nov 6 (Reuters) - Teva Pharmaceutical Industries TEVA.TA reported a larger than expected rise in third-quarter profit, boosted by strong sales of copycat medicines and its branded drugs to treat migraines and Huntington's disease. The world's largest generic drugmaker said on Wednesday it earned 69 cents per diluted share excluding one-time items in the July-September quarter, up from 60 cents per share a year earlier.
T

Teva Reports Q3 2024 Results, Driven By Generics And Innovative Portfolio, Raises 2024 Outlook

BRIEF-Teva Reports Q3 2024 Results, Driven By Generics And Innovative Portfolio, Raises 2024 Outlook Nov 6 (Reuters) - Teva Pharmaceutical Industries Ltd TEVA.TA : TEVA ANNOUNCES STRONG FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2024, LED BY GENERICS PERFORMANCE AND INNOVATIVE PORTFOLIO GROWTH; RAISES 2024 FINANCIAL OUTLOOK INCLUDING ON REVENUES, A
T

Teva Pharmaceutical Industries Ltd <TEVA.N> expected to post earnings of 66 cents a share - Earnings Preview

Teva Pharmaceutical Industries Ltd expected to post earnings of 66 cents a share - Earnings Preview Teva Pharmaceutical Industries Ltd TEVA.N , TEVA.K is expected to show a rise in quarterly revenue when it reports results on November 6 for the period ending September 30 2024 The Tel Aviv-yafo Israel-based company is expected to report a 7.0% increase in revenue to $4.119 billion from $3.85 billion a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
T

Financial Times - Nov 1

PRESS DIGEST- Financial Times - Nov 1 Nov 1 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines - Rival creditor group offers Thames Water emergency loan at lower rate - British aerospace pioneer Reaction Engines collapses into administration - GB News fined 100,000 stg in first financial sanction by Ofcom - EU fines world's largest generic drugmaker Teva for hindering competition Overview -
B
T

Drugmakers Apotex, Heritage to pay $49 mln to resolve states' price-fixing claims

Drugmakers Apotex, Heritage to pay $49 mln to resolve states' price-fixing claims By Mike Scarcella Oct 31 (Reuters) - Generic drugmakers Apotex and Heritage Pharmaceuticals have agreed to pay nearly $50 million to settle claims by Connecticut and other states that accused them of conspiring to artificially inflate prices. Heritage, a subsidiary of India’s Emcure Pharmaceuticals, and Apotex said they will cooperate with the states in continuing litigation against dozens of other drugmakers acc
P
T

Teva hit with $503 mln EU antitrust fine for disparaging rival product

UPDATE 1-Teva hit with $503 mln EU antitrust fine for disparaging rival product Adds response from Teva in paragraph 2 and paragraphs 6-8, fresh Vestager comments, details By Sudip Kar-Gupta BRUSSELS, Oct 31 (Reuters) - Teva TEVA.TA , the world's largest generic drugmaker, was hit on Thursday with a 462.6 million euro ($503 million) EU antitrust fine for abusing its dominant position to delay competition to its blockbuster multiple sclerosis medicine Copaxone .
T

Teva fined $503 mln by EU for disparaging rival product

Teva fined $503 mln by EU for disparaging rival product BRUSSELS, Oct 31 (Reuters) - The European Commission has fined Teva TEVA.TA , the world's largest generic drugmaker, 462.6 million euros ($503 million) for abusing its dominant position to delay competition to its blockbuster multiple sclerosis medicine Copaxone, confirming a Reuters exclusive .
T

Amicus Therapeutics Enters License Agreement With Teva Pharmaceuticals

BRIEF-Amicus Therapeutics Enters License Agreement With Teva Pharmaceuticals Oct 17 (Reuters) - Amicus Therapeutics Inc FOLD.O : AMICUS THERAPEUTICS ANNOUNCES SETTLEMENT OF GALAFOLD® (MIGALASTAT) PATENT LITIGATION WITH TEVA AMICUS THERAPEUTICS INC - ENTERS LICENSE AGREEMENT WITH TEVA PHARMACEUTICALS AMICUS THERAPEUTICS INC - TEVA TO MARKET GENERIC GALAFOLD IN U.S.
T

Wall Street Journal - Oct 11

PRESS DIGEST-Wall Street Journal - Oct 11 Oct 11 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. - China-owned social-media platform TikTok is laying off employees as part of a revamp of its content-moderation operations. It plans to invest $2 billion globally in trust and safety initiatives in 2024, aiming to improve efficacy.
N
T

Teva to pay $450 million to resolve US kickback, price-fixing cases

UPDATE 1-Teva to pay $450 million to resolve US kickback, price-fixing cases Adds details on settlement, background of case throughout By Nate Raymond BOSTON, Oct 10 (Reuters) - Teva Pharmaceutical Industries Ltd TEVA.TA has agreed to pay $450 million to resolve allegations it used charities that help cover Medicare patients' out-of-pocket drug costs as a means to pay kickbacks to boost sales of its multiple sclerosis drug Copaxone and conspired to fix prices for generic drugs.
R
T

Teva agrees to pay $450m to resolve kickback allegations, US Justice Dept says

Teva agrees to pay $450m to resolve kickback allegations, US Justice Dept says WASHINGTON, Oct 10 (Reuters) - New Jersey-based drugmaker Teva has agreed to pay $450 million to resolve allegations that it violated an anti-kickback statute and the False Claims Act, the U.S. Justice department said in a statement on Thursday. "Kickbacks designed to induce referrals or purchases of healthcare goods or services distort physician and patient decision-making, thwart competition and bypass controls put
T

Teva Prolia Biosimilar Candidate Is Accepted For Review By U.S. FDA And EU EMA

BRIEF-Teva Prolia Biosimilar Candidate Is Accepted For Review By U.S. FDA And EU EMA Oct 8 (Reuters) - Teva Pharmaceutical Industries Ltd TEVA.TA : TEVA PROLIA® (DENOSUMAB) BIOSIMILAR CANDIDATE IS ACCEPTED FOR REVIEW BY U.S. FDA AND EU EMA TEVA PHARMACEUTICAL INDUSTRIES LTD - FDA AND EMA DECISIONS EXPECTED IN 2H 2025 Source text for Eikon: ID:nGN
T

Abu Dhabi's ADNOC to buy German chemicals firm Covestro for $16 bln

UPDATE 6-Abu Dhabi's ADNOC to buy German chemicals firm Covestro for $16 bln ADNOC to pay 62 euros per Covestro share, take on 3 bln in debt To buy additional 1.2 bln euros worth of new shares in Covestro Covestro shares jump 3.7% to a three-year high Deal could fuel debate over foreign takeovers of German firms Adds Covestro supervisory board's advisers in paragraph 26 By Ludwig Burger and Yousef Saba BERLIN/DUBAI Oct 1 (Reuters) - Abu Dhabi's ADNOC has struck a deal to buy German chemicals mak
B
C
G
N
O
T
U
V

Copycat drugmakers will be low-key obesity winners

BREAKINGVIEWS-Copycat drugmakers will be low-key obesity winners The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan LONDON, Sept 25 (Reuters Breakingviews) - Generic drug makers are getting ready to take a bite out of the booming weight loss market. Firms like Teva Pharmaceutical TEVA.TA and Sandoz SDZ.S have started to launch the first copycats from the class of drugs which include Novo Nordisk's NOVOb.CO hugely successful Ozempic and Wegovy
T

Teva Says Tev-‘749 Meets Primary Endpoint In Phase 3 Study

BRIEF-Teva Says Tev-‘749 Meets Primary Endpoint In Phase 3 Study Sept 21 (Reuters) - Teva Pharmaceutical Industries Ltd TEVA.TA : TEVA PRESENTS NEW PHASE 3 EFFICACY, SAFETY AND TOLERABILITY DATA FROM SOLARIS TRIAL EVALUATING TEV-‘749 (OLANZAPINE) AS A ONCE-MONTHLY SUBCUTANEOUS LONG-ACTING INJECTABLE FOR ADULT PATIENTS DIAGNOSED WITH SCHIZOPHREN
T

Novo says Ozempic 'very likely' to be on 2027 Medicare negotiation list, Bloomberg News reports

Novo says Ozempic 'very likely' to be on 2027 Medicare negotiation list, Bloomberg News reports Sept 17 (Reuters) - Danish drugmaker Novo Nordisk NOVOb.CO expects its diabetes drug Ozempic will "very likely" be on the U.S. government's 2027 list of price negotiations, Bloomberg News reported on Tuesday citing a company executive . Part of 2022's Inflation Reduction Act allows Medicare to negotiate prices for prescription drugs that had been particularly expensive for the federal health program w
P
T

Baltimore to take drug distributors to trial over opioids

UPDATE 1-Baltimore to take drug distributors to trial over opioids Adds comment from Cencora in paragraph 4 By Brendan Pierson Sept 16 (Reuters) - The city of Baltimore is scheduled to go to trial this week in its $11 billion lawsuit accusing drug distributors McKesson MCK.N and Cencora COR.N of fueling an epidemic of opioid addiction and overdose deaths.
T
W
M



स्थितियाँ

लोकप्रिय परिसंपत्तियाँ

अस्वीकरण: XM Group के सत्व केवल निष्पादन वाली सेवा और हमारी ऑनलाइन व्यापार सुविधा में पहुँच प्रदान करते हैं, ताकि व्यक्ति वेबसाइट पर या उसके जरिए उपलब्ध सामग्री को देख सके और/या उसका उपयोग कर सके। इसका प्रयोजन इसे बदलना या विस्तार देना नहीं है, न ही वह इसे बदलता या विस्तार देता है। इस तरह की पहुँच हमेशा ही निम्नलिखित के अधीन रहेगी: (1) नियम और शर्तें; (2) जोखिम चेतावनियाँ; और (3) पूर्ण अस्वीकरण। इसलिए ऐसी जानकारी सामान्य सूचना से अधिक कुछ भी नहीं है। विशेष रूप से, कृपया इससे अवगत रहें कि हमारी ऑनलाइन व्यापार सुविधा की सामग्रियाँ न तो किसी चीज का अनुरोध करती हैं, न ही वित्तीय बाजारों में प्रवेश करने की पेशकश ही करती हैं। किसी भी वित्तीय बाजार में व्यापार करने के साथ आपकी पूँजी को उल्लेखनीय जोखिम है।

हमारी ऑनलाइन व्यापार सुविधा में प्रकाशित सभी सामग्रियाँ शैक्षणिक/सूचनात्मक प्रयोजनों मात्र के लिए हैं, और इनमें वित्तीय, निवेश टैक्स या व्यापार सलाह और सुझाव नहीं हैं - न ही ऐसा समझना चाहिए कि इनमें ये सब हैं; न ही इनमें हमारी व्यापार कीमतों का अभिलेख है; न ही इनमें किसी वित्तीय उपकरण में लेन-देन करने का निमंत्रण या अनुरोध है; न ही ये आपको अवांछित वित्तयी प्रोमोशन पेश करती हैं।

इस वेबसाइट में मौजूद कोई भी तृतीय पक्षीय सामग्री, तथा XM द्वारा तैयार की गई सामग्रियाँ, जैसे: अभिप्राय, समाचार, अनुसंधान, विश्लेषण, कीमतें और अन्य सूचनाएँ या तृतीय पक्षों की साइटों के लिंक, "जैसा-है-वैसा" के आधार पर बाजार के बारे में सामान्य टिप्पणी के रूप में उपलब्ध कराई गई हैं, और वे निवेश हेतु सलाह नहीं हैं। जिस हद तक कीसी सामग्री को निवेश अनुसंधान मान लिया जाता है, उस हद तक आपको ध्यान में रखना होगा और इसे स्वीकार करना होगा कि वह सामग्री इस उद्देश्य से और निवेश अनुसंधान की स्वतंत्रता को बढ़ावा देने के लिए कानूनी आवश्यकताओं के मुताबिक, तैयार नहीं की गई है, और इसलिए उसे प्रासंगिक कानूनों और विनियमों के तहत विपणन संप्रेषण माना जाएगा। कृपया सुनिश्चित करें कि आपने गैर-आश्रित निवेश के बारे में हमारी सूचना को पढ़ और समझ लिया है। पीछे दी गई जानकारी के बारे में अनुसंधान और जोखिम चेतावनी यहाँ उपलब्ध है।

जोखिम की चेतावनी: आपकी पूँजी जोखिम में है। लीवरेज वाले उत्पाद सबके उपयुक्त नहीं होते हैं। कृपया हमारे जोखिम खुलासे पर विचार करें।